Exclusive Summary

• Core patents for the originator product (Eli Lilly's Forteo) have expired globally, and generic/biosimilar entries are already approved in the US, EU, and other markets, giving Chinese suppliers a structural cost advantage for distribution partnerships.
• Over 200 million people worldwide suffer from osteoporosis, with 8.9 million fractures annually; teriparatide addresses a large, underserved patient population—especially severe and high-fracture-risk cases—representing a multi-billion dollar global market opportunity.
• Teriparatide is the only widely established anabolic bone-forming agent recommended by major guidelines (NOF, ESCEO/IOF, CSOBMR) for high-risk osteoporosis patients, giving it a defensible clinical niche versus antiresorptive drugs like bisphosphonates.
• The US originator price exceeds $3,000/month, while Chinese-manufactured generics can be supplied at 50–80% lower cost, making Chinese suppliers highly attractive to overseas generic licensees and distributors in emerging and regulated markets alike.